UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

December 11, 2024

Elacestrant plus abemaciclib demonstrated clinically important efficacy in ER-positive/HER2-negative advanced or metastatic breast cancer.

December 11, 2024

Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.

December 11, 2024

Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.

December 01, 2024

Neil P. Shah, MD, PhD, highlights key recent changes to the CML NCCN guidelines and details anticipated data for 2025.

November 27, 2024

Alan P. Venook, MD, describes challenges implementing NCCN guidelines into practice in rectal, colon, and biliary tract cancers, and advancements from 2024.

November 25, 2024

Alan P. Venook, MD, highlights notable NCCN guideline updates in HCC, considerations for implementing the changes in the clinic, and next steps in HCC.

November 11, 2024

UCSF Life Sciences Building will bring research, innovation, specialty care clinics, and world-class cancer therapy to San Francisco’s central waterfront.

November 05, 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

October 31, 2024

Hope Rugo, MD, FASCO, discusses the FDA approval of inavolisib, how it will be incorporated into care, and the patient population evaluated in INAVO120.

October 23, 2024

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.

October 17, 2024

Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.

October 10, 2024

Dr Taylor discusses the significance of the FDA approval of vorasidenib for patients with IDH-positive grade 2 astrocytoma or oligodendroglioma.

October 02, 2024

Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.

September 25, 2024

Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.

September 24, 2024

Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease.

September 18, 2024

Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.

September 18, 2024

Panelists discuss how management and monitoring for pneumonitis and cardiotoxicity in trastuzumab deruxtecan (T-DXd) is similar to trastuzumab emtansine (T-DM1), while also emphasizing the need for awareness of adverse effects such as peripheral neuropathy, thrombocytopenia, and hepatotoxicity, along with strategies for their management and when to consider therapy modifications.

September 16, 2024

Terence W. Friedlander, MD, discusses adverse effects that are associated with standard enfortumab vedotin in bladder cancer.

September 16, 2024

Researchers will investigate aggressive prostate cancer from a mechanistic, biomarker and therapeutic perspective.

September 11, 2024

Experts on breast cancer provide clinical insights on the management of pneumonitis associated with trastuzumab deruxtecan.